CYP2C8, CYP2C9, and CYP2C cluster
Ordering Recommendation
Use to assess genetic risk of abnormal drug metabolism for drugs metabolized by enzymes coded by CYP2C8, CYP2C9, and the 2C cluster variant (rs12777823).
May aid in drug selection and dose planning for drugs metabolized by enzymes coded by CYP2C8, CYP2C9 and the 2C cluster variant (rs12777823).
New York DOH Approval Status
Specimen Required
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Refrigerated.
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Methodology
Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
Performed
Varies
Reported
5-10 days
Reference Interval
By report
Interpretive Data
Refer to report
Laboratory Developed Test (LDT)
Note
Whole blood is the preferred specimen. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting.
Hotline History
Hotline History
CPT Codes
81227; 81479
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2008931 | CYP2C9 Phenotype | 79716-7 |
3001502 | 2C8/2C9 Specimen | 66746-9 |
3001503 | CYP2C8 Genotype | 78972-7 |
3001504 | CYP2C9 Genotype | 46724-1 |
3001505 | 2C8/2C9 Interpretation | 50398-7 |
3004497 | CYP2C8 Phenotype | 81259-4 |
3004499 | CYP2C Cluster Geno | 101785-4 |
3004500 | CYP2C Cluster Pheno | 81259-4 |
3016871 | EER CYP2C8 CYP2C9 CYP2C Cluster | 11526-1 |
Aliases
- 2C8
- 2C9
- celecoxib
- Coumadin
- CYP2C8
- CYP2C9
- CYP2C9 cluster
- Cytochrome P450 2C8
- Cytochrome P450 2C9 Genotype
- flurbiprofen
- glibenclamide
- gliclazide
- glimepiride
- ibuprofen
- lornoxicam
- Mayzent
- meloxicam
- NSAIDS
- phenytoin
- piroxicam
- siponimod
- sulfonylureas
- tenoxicam
- tolbutamide
- warfarin